• Sumitomo Pharma America will present enzomenib and nuvisertib clinical data at the American Society of Hematology meeting December 12-15, 2026.
• Enzomenib presentations will include initial pivotal Phase 2 results in relapsed or refractory acute leukemia with KMT2A rearrangements.
• A completed enzomenib dose-optimization study showed generally tolerable treatment with clinical activity in relapsed or refractory NPM1-mutated acute leukemia.
• Preliminary nuvisertib-momelotinib results showed clinical responses and generally tolerable treatment in myelofibrosis, supporting Phase 3 development for patients with anemia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.